Moderna (MRNA) Non-Current Deffered Revenue (2017 - 2026)

Moderna (MRNA) has reported Non-Current Deffered Revenue for 10 consecutive years, with $147.0 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Non-Current Deffered Revenue rose 126.15% year-over-year to $147.0 million in Q2 2026; TTM through Jun 2026 was $147.0 million, a 126.15% increase from a year earlier, with the FY2025 full-year figure at $153.0 million, up 163.79% from the prior year.
• Non-Current Deffered Revenue was $147.0 million for Q2 2026 at Moderna, down from $154.0 million in the prior quarter.
• Over five years, Non-Current Deffered Revenue peaked at $692.0 million in Q2 2023 and troughed at $58.0 million in Q1 2024.
• A 5-year average of $242.8 million and a median of $153.5 million in 2025 frame the typical range for Non-Current Deffered Revenue.
• Across the five-year window, Non-Current Deffered Revenue plunged 91.38% in 2024 and soared 165.52% in 2026, its largest moves.
• Over 5 years, Non-Current Deffered Revenue stood at $673.0 million in 2022, then slumped by 87.67% to $83.0 million in 2023, then tumbled by 30.12% to $58.0 million in 2024, then surged by 163.79% to $153.0 million in 2025, then dropped by 3.92% to $147.0 million in 2026.
• The last three Non-Current Deffered Revenue figures came in at $147.0 million (Q2 2026), $154.0 million (Q1 2026), and $153.0 million (Q4 2025), per Business Quant data.